Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Abdominopelvic imaging in the follow-up of testicular germ-cell tumors in adults: recommendations of the Scrotal and Penile Imaging Working Group of the European Society of Urogenital Radiology.European radiology · 2025Guideline
- Guideline recommendations versus real-world management in early-stage testicular cancer: a multicenter survey of contemporary practice.Therapeutic advances in medical oncology · 2026Article
- Testicular Cancer: Diagnosis, Treatment, and Biomarker Advances.Research and reports in urology · 2026Review
- [Follow-up in patients with testicular germ cell tumors-an update].Urologie (Heidelberg, Germany) · 2025Review
- Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study.Acta oncologica (Stockholm, Sweden) · 2025Article
- [Stage-dependent treatment of seminomas].Urologie (Heidelberg, Germany) · 2024Article
- Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.Clinical genitourinary cancer · 2024Article
- Late side effects of testicular cancer and treatment: a comprehensive review.Discover oncology · 2024Review
- First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).European urology open science · 2024Article
- Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy.Annals of nuclear medicine · 2024Article
- When should factorial designs be used for late-phase randomised controlled trials?Clinical trials (London, England) · 2024Review
- Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers.Cancers · 2024Review
- Testicular Tumors.Deutsches Arzteblatt international · 2023Review
- Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.British journal of cancer · 2023Article
- Redefining surveillance strategies: innovations in testicular cancer care.Translational andrology and urology · 2023Article
- Novel approaches to redesign surveillance strategies following orchiectomy for localized testicular cancer: a narrative review.Translational andrology and urology · 2023Review
- German specialists treating testicular cancer follow different guidelines with resulting inconsistency in assessment of retroperitoneal lymph-node metastasis: clinical implications and possible corrective measures.World journal of urology · 2023Article
- Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review.European urology open science · 2022Review
- The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 1 country.
Funding
Abstract
purposeSurvival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation is vital. The Trial of Imaging and Surveillance in Seminoma Testis (TRISST) assessed whether magnetic resonance images (MRIs) or a reduced scan schedule could be used without an unacceptable increase in advanced relapses.
methodsA phase III, noninferiority, factorial trial. Eligible participants had undergone orchiectomy for stage I seminoma with no adjuvant therapy planned. Random assignment was to seven CTs (6, 12, 18, 24, 36, 48, and 60 months); seven MRIs (same schedule); three CTs (6, 18, and 36 months); or three MRIs. The primary outcome was 6-year incidence of Royal Marsden Hospital stage ≥ IIC relapse (> 5 cm), aiming to exclude increases ≥ 5.7% (from 5.7% to 11.4%) with MRI (
resultsSix hundred sixty-nine patients enrolled (35 UK centers, 2008-2014); mean tumor size was 2.9 cm, and 358 (54%) were low risk (< 4 cm, no rete testis invasion). With a median follow-up of 72 months, 82 (12%) relapsed. Stage ≥ IIC relapse was rare (10 events). Although statistically noninferior, more events occurred with three scans (nine, 2.8%) versus seven scans (one, 0.3%): 2.5% absolute increase, 90% CI (1.0 to 4.1). Only 4/9 could have potentially been detected earlier with seven scans. Noninferiority of MRI versus CT was also shown; fewer events occurred with MRI (two [0.6%]
conclusionSurveillance is a safe management approach-advanced relapse is rare, salvage treatment successful, and outcomes excellent, regardless of imaging frequency or modality. MRI can be recommended to reduce irradiation; and no adverse impact on long-term outcomes was seen with a reduced schedule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.